|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 9, Num. 2, 2004, pp. 114-117
|
Untitled Document
Middle East Fertility Society Journal, Vol. 9, No. 2, 2004, pp. 114-117
DEBATE
Ovarian hyperstimulation syndrome: are preventive measures
effective?
Comment by: Momen A. Kamel, M.D. Assiut, Egypt.
Code Number: mf04020
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic life-threatening
complication of ovarian stimulation in Assisted Reproductive Techniques. In
spite of the extensive researches and articles published upon the preventive
measures for the syndrome, there is a feeling that we are still faraway from
an effective and completely safe preventive strategy for the syndrome, which
at the same time will not jeopardize the oocytes and embryos quality as well
as the pregnancy rate. In the literature the authors gave an outstanding different
opinions on the same preventive option. In the following we try to summarize
the value of each preventive option and the different opinions on each option.
Defining patients at risk and adjusting the stimulation protocol
The first important step of prevention is the identification of risk factors,
in order to individualize the patient's stimulation regimen. PCOS patients are
the most vulnerable group for the development of the syndrome. While it is believed
that both E2 and ultrasound monitoring is necessary, it is insufficient as most
IVF centers still report the occurrence of severe forms of OHSS, even though
such monitoring is practiced (1). A serum E2 level of 12,315 pmol/ L (3,354 pg/
ml) on day 11 of ovarian stimulation gives a sensitivity and specificity of 85%
for the detection of women at risk for OHSS (2). Strict monitoring does however
allow the application of a number of preventive measures when ovarian response
is exaggerated.
Canceling the cycle
Canceling the cycle and withholding HCG is the only method which totally avoids
the risk of OHSS in ovarian induction cycle or in IVF. All other procedures
usually succeed in decreasing either the risk or the severity of OHSS rather
than totally preventing it (3). When GnRH agonists or antagonists are not used,
one should remain vigilant, since a spontaneous LH peak may still occur, resulting
in a pregnancy that is sometimes associated with OHSS complications (4).
Intravenous albumin
The suggestion that i.v. albumin might prevent the development of severe OHSS
was first made in 1993 (5). In the literature, the dose of i.v. albumin varies
between 20-50 g and the time of its administration was either; before, during
or immediately after oocyte retrieval. This dose was not adjusted according
to the serum albumin level. A Cochrane Review on the use of i.v. albumin to
prevent severe OHSS, included five randomized controlled trials that enrolled
378 women (193 in the albumin - treated group and 185 in the control group).
A meta-analysis of the five included trials showed a significant reduction
in severe OHSS by administration of human albumin, but it did not lead to complete
prevention. No second dose was given later on except in one study (6). Kamel
in 2003 adjusted the dose according to the drop of serum albumin level (7).
Other volume expanders such as hydroxyethyl starch
As an alternative to human albumin, 1000 ml 6% hydroxyethyl starch solution
may be infused at the time of oocyte collection, followed by another 500 ml
48 h later (8). Although there was no significant reduction in the severe OHSS
cases, but there was a high significant decrease in moderate OHSS in the i.v.
starch group. In a prospective randomized, double -blind, placebo - controlled
study hydroxyethyl starch significantly reduced the incidence of OHSS (9).
Coasting
In a Cochrane review D' Angelo and Amso assess the effect of "Coasting" (Withholding
gonadotrophins) as a preventive strategy in the management of OHSS in comparison
with "early unilateral follicular aspiration (EUFA)" or other interventions.
Out of thirteen studies surveyed, only one trial met the inclusion criteria.
Their conclusion was that there is a lack of randomized controlled trials for
where coasting is compared with no coasting or other interventions such as
embryo freezing or i.v. albumin infusion for prevention of OHSS. There is insufficient
evidence to determine if coasting is an effective strategy for preventing OHSS
(10). Another systematic review of coasting as a procedure to avoid OHSS in
IVF patients was done by Delvinge and Rosenberg in 2002. They concluded that,
while coasting does not avoid totally the risk of OHSS, it decreases its incidence
in high- risk patients (11). Coasting was applied up to 12% of all cycles.
This means that some cycles were coasted unnecessarily. If coasting is prolonged
for >4 days there is a significant decrease in both implantation and pregnancy
rates (12).
Intravenous albumin versus coasting
There is lack of prospective randomized controlled trials comparing coasting
with i.v. albumin in preventing OHSS. Chen et al., 2003 in a retrospective
comparative study found no statistically significant difference in the entire
outcome examined. Coasting was as effective as i.v. albumin in preventing OHSS
in high-risk patients but yields inferior pregnancy rates (13).
Intravenous albumin versus no treatment
Although i.v. albumin administration in different studies as well as in a Cochrane
review showed a protective value against OHSS, one recent study showed different
opinion. Bellver et al., 2003 in a study that included 976 women comparing 40
g albumin at the time of oocyte retrieval with no treatment showed that, i.v.
albumin on the day of oocyte retrieval is not a useful means of preventing the
development of moderate- severe OHSS. This study included only 154 (15.6 %) PCOS
patients out of the 988 included patients. At the same time coasting was done
in 11 patients (14). There is no standardization of the protocol of induction
either with the down regulation or type of gonadotropins used. The starting dose
of gonadotropins is high. There was a mix between minority of PCOS patients in
a majority of non- PCOS patients, who are not at risk of OHSS, but pushed for
the syndrome by the aggressive induction protocol.
Embryo freezing
In a Cochrane review D' Angelo and Amso evaluated the effectiveness of cryopreservation
(embryo freezing) for the prevention of OHSS. Out of 17 studies included only
two of which met the inclusion criteria. When cryopreservation was compared
with i.v. albumin no difference was found in all the outcomes examined. When
elective cryopreservation of all embryos was compared with fresh embryo transfer
no difference was found in all the outcomes examined. It seems that cryopreservation
of all embryos has no value for preventing the early type of the syndrome and
it may of value in preventing its late type if pregnancy will occur. The conclusion
was that there is insufficient evidence to support routine cryopreservation
and insufficient evidence for the relative merits of i.v. albumin versus cryopreservation
(15).
Luteolysis induced by a gonadotropin- releasing hormone agonist
Kol in 2004 revised the studies published over the past 15 years on the use
GnRH agonist for ovulation triggering as a means to prevent OHSS. The conclusion
was that; controlled ovarian stimulation protocols based on GnRH antagonist
to prevent premature LH rise and GnRH agonist for ovulation triggering provide
a safe and OHSS - free clinical environment. The mechanism of action involves
complete, quick, and irreversible luteolysis. Adequate luteal support compensates
for leuteolysis. It is clear that in this regimen, no HCG was used. It should
be emphasized that the clinical findings attributable to mild OHSS are an integral
part of most cases of ovulation induction in IVF. Yet some reports of moderate
cases were also described. A practical major limitation of Gn RHa- induced
ovulation is that it is not applicable in IVF stimulated cycles during which
pituitary down -regulation with a GnRH agonist is used, which is used routinely
by most IVF programs until recently (16).
Follicular aspiration
Early unilateral follicular aspiration (EUFA) 10-12 h after hCG administration
was compared with coasting in a prospective randomized study. Fewer oocytes
were recovered in the coasting group, but fertilization, embryonic cleavage
and pregnancy rates were similar. Neither method completely prevented the occurrence
of severe OHSS. As the method is not completely preventive for the syndrome
as well as its invasive nature, necessitating two oocyte retrievals, explain
why it has been attempted less often than coasting.
Oral hydration with increased protein intake
An advice to increase oral hydration and protein intake should be given to
all women at risk to develop OHSS. This may prevent haemoconcentration and
increase urinary excretion of vasoactive mediators responsible for the syndrome
(17).
In- vitro maturation (IVM) of oocytes
IVM is one of the new assisted reproductive technologies for the infertile
women with PCOS, especially those with history of OHSS. This may eliminate
the risk of the syndrome for this group of patients (18).
CONCLUSION
We see from the previous review of the available preventive options for OHSS,
that there is no agreement on each preventive strategy. This may be due -at least
in part- to the lack of welldesigned prospective randomized controlled clinical
trials with sufficient number of cases. The sample should be uniform in each
study with no mix between PCOS patients and other risk groups. The end point
in each study, as well as the points of comparison should be clear. Until this
I feel that clinical judgement and dose adjustment should be the first line of
prevention. There should be a reassessment of i.v. albumin administration with
dose adjustment according to the serum albumin level against coasting. Luteolysis
with GnRH- a after antagonist will have a limited role until the clinical experience
with the antagonist will build -up. Oral hydration with increased protein intake
starting from day 8 of the stimulation cycle may be of help with other preventive
measures. Other measures as EUFA and cryopeservation have limited practical preventive
value. IVM may be of help in PCOS patients in the
future.
REFERENCES
- Delvigne A, Dabois M, Battheu
B, Bassil S, Meuleman C, De Sutter P, Rodesch C, Janssens P, Remacle P,
Gordts S, et al. The ovarian hyperstimulation syndrome in in -vitro fertilization
: a Belgian multicentric study II multiple discriminate analysis for risk
prediction.
Hum Reprod 1993;8 : 1361-71.
- D' Angelo A, Davies R, Salah
E, Nix BA, Amso NN. Value of serum estradiol level for preventing ovarian
hyperstimulation syndrome : a retrospective case control study. Fertil Steril
2004 ; 81(2):
332-6.
- 3-Delvigne A, Rozenberg S. Epidemiology
and prevention of ovarian hyperstimulation syndrome (OHSS) : a review.
Hum Reprod update 2002; 8(6): 559-77.
- Liptiz S, Ben- Rafel Z, Bider
D, Shalev J, Mashiach S. Quintuplet pregnancy and third degree ovarian
hyperstimulation despite withholding human chorionic gonadotrophin. Hum Reprod
1991;6: 1478-9.
- Asch RH, Lvery G, Goldsman M,
Frederick Jl, Stone S, Balmaceda JP. The use of intravenous albumin in
patients at hight risk for severe ovarian hyperstimulation syndrome. Hum
Reprod 1993;
8: 1015-20.
- Aboulghar M, Evers JH, Al- Inany
H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome.
Cochrane Database Syst. Rev 2002; (2): CD 001302.
- Kamel MA. Prophylactic intravenous
albumin in ovarian hyperstimulation syndrome regimen depending on serum
proteien level. Abstracts of the 2nd Annual Congress of the Mediterranean
Society for
Reproductive Medicine, Alexandria Egypt 2003.
- Graf MA, Fischer R, Naether OGJ,
Baukloh V, Taferl J, Nuckel M. Reduced incidence of ovarian hyperstimulation
syndrome by prophylactic infusion of hydroxaethl starch solution in an
in -vitro fertilization programme. Hum Reprod 1997; 12: 2599-602.
- Konig E, Bussen S, Sutterlin
M, Steck T. Prophylactic intravenous hydroxyethyl starch solution prevents
moderate- sever ovarian hyperstimulation in in -vitro fertilization patients:
a prospective, randomized, double -blind and placebo - controlled study.
Hum Reprod 1998;13: 2421-4.
- D' Angelo A, Amso N. "Coasting" (Withholding
Gonadotrophins) for preventing ovarian hyperstimulation syndrome Cochrane
Data base Syst Rev 2002; (3): CD 002811.
- Delvinge A, Rozenberg S. A qualitative systemic
review of coasting, a procedure to avoid ovarian hyperstimulation syndrome
in IVF patients. Human Repot Update 2002; 8(3): 291-6.
- Isaza V, Garcia- Velasco JA, Aragones M, Remohi
J, Simon C, Pellicer A. Oocyteand embryo quality after coasting : the experience
of oocyte donation Hum Reprod 2002; 17(7): 1777-82.
- Chen CD, Chao KH, Yang JH, Chen Su, Ho HN, Yang
YS. Comparison of coasting and intravenous albumin in the prevention of
ovarian hyperstimulation syndrome. Fertil Steril 2003; 80(1): 86-90.
- Bellver J, Munoz EA, Ballesteros A, Soares SR, Bosch E, Simon C, Pellicer
A, Remohi J. Intravenous albumin does not prevent moderate- severe ovarian
hyperstimulation
syndrome in high- risk IVF patients: a randomized controlled study. Hum Reprod
2003; 18 (11) : 311-4.
- D' Angelo A, Amso N. Embryo freezing for preventing
Ovarian Hyperstimulation Syndrome. Cochrane Data base Syst Rev 2002;(2):
CD002806.
- Kol S. Luteolysis induced by a gonadotropin -
releasing hormone agonist is the key to prevention of ovarian hyperstimulation
syndrome. Fertil Steril 2004; 81(1) : 1-5.
- Brinsden P. Guidelines for the management of patient
at risk of developing ovarian hyperstimulation syndrome. In: A text book
of In Vitro Fertilization and Assisted Reproduction, the Bourn Hall guide
to clinical
and laboratory practice. Parthenon publishing group. New York, London 1999;485-6.
- Liu JY, Qian Y, Mao YD, Ding W, Yang NM. In Vitro
maturation, fertilization and embryo transfer of human immature oocyte
(in Process Citation). Zhonghua Fu, Chan Ke, Za Zhi 2003;38(4):230-2.
Momen A. Kamel, M.D.
Professor of Obstetrics and Gynecology
Assiut University Hospital,
and Assiut Center for IVF and ICSI
© Copyright 2004 - Middle East Fertility Society
|